Intellia Therapeutics (NTLA) Stock Forecast & Price Target

Compare

4,578 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NTLA Analyst Ratings

Moderate Buy

9 Buy

12 Hold

1 Sell

Based on 22 analysts giving stock ratings to

Intellia

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NTLA Stock 12 Month Forecast

Average Price Target

$15.97

▲(87.44% Upside)

Based on 22 Wall Street analysts offering 12 month price targets for Intellia Therapeutics in the last 3 months. The average price target is $15.97 with a high forecast of $54.00 and a low forecast of $4.00. The average price target represents a 87.44% change from the last price of $8.52.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","16":"$16","29":"$29","42":"$42","55":"$55"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":54,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$54.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.97,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.97</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,16,29,42,55],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.62,15.803076923076922,18.986153846153847,22.16923076923077,25.35230769230769,28.535384615384615,31.71846153846154,34.90153846153846,38.08461538461538,41.26769230769231,44.45076923076923,47.63384615384615,50.816923076923075,{"y":54,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.62,12.877692307692307,13.135384615384615,13.393076923076922,13.65076923076923,13.908461538461538,14.166153846153845,14.423846153846153,14.681538461538462,14.939230769230768,15.196923076923078,15.454615384615385,15.712307692307693,{"y":15.97,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.62,11.956923076923076,11.293846153846154,10.63076923076923,9.967692307692307,9.304615384615385,8.641538461538461,7.978461538461538,7.315384615384615,6.6523076923076925,5.989230769230769,5.326153846153846,4.663076923076924,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.81,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.73,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.66,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.32,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.09,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.66,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.64,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.16,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.88,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.49,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.76,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.62,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$54.00

Average Price Target$15.97

Lowest Price Target$4.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Myles Minter

William Blair

―

Hold

―

Reiterated

11/15/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Intellia Therapeutics (NASDAQ: NTLA) and Acrivon Therapeutics, Inc. (NASDAQ: ACRV)we reiterate our Market Perform rating on Intellia as we await clarity on safety and a path forward for nex-z

Debanjana Chatterjee

JonesTrading

―

Hold

―

Downgraded

11/11/25

JonesTrading downgrades Intellia Therapeutics (NTLA) to a Hold

Andy Chen

Wolfe Research

―

Hold

―

Downgraded

11/11/25

Intellia Therapeutics downgraded to Peer Perform from Outperform at Wolfe ResearchIntellia Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research

Jonathan Miller

Evercore ISI

$17→$8

Hold

-6.10%

Downside

Downgraded

11/11/25

Intellia Therapeutics (NTLA) was downgraded to a Hold Rating at Evercore ISI

Unknown Analyst

Wedbush

Not Ranked

Wedbush

$9→$7

Hold

-17.84%

Downside

Reiterated

11/11/25

Wedbush Keeps Their Hold Rating on Intellia Therapeutics (NTLA)

Joon Lee

Truist Financial

$25→$14

Buy

64.32%

Upside

Reiterated

11/10/25

Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NASDAQ: NTLA), Tandem Diabetes Care (NASDAQ: TNDM) and Palvella Therapeutics (NASDAQ: PVLA)

Mitchell Kapoor

H.C. Wainwright

$18→$15

Buy

76.06%

Upside

Reiterated

11/10/25

Intellia Therapeutics price target lowered to $15 from $18 at H.C. WainwrightIntellia Therapeutics price target lowered to $15 from $18 at H.C. Wainwright

Jay Olson

Oppenheimer

$33→$27

Buy

216.90%

Upside

Reiterated

11/07/25

Intellia Therapeutics price target lowered to $27 from $33 at OppenheimerIntellia Therapeutics price target lowered to $27 from $33 at Oppenheimer

Silvan Tuerkcan

Citizens JMP

$29→$21

Buy

146.48%

Upside

Reiterated

11/07/25

Intellia Therapeutics price target lowered to $21 from $29 at Citizens JMPIntellia Therapeutics price target lowered to $21 from $29 at Citizens JMP

Yanan Zhu

Wells Fargo

$17→$12

Hold

40.85%

Upside

Reiterated

11/07/25

Intellia Therapeutics price target lowered to $12 from $17 at Wells FargoIntellia Therapeutics price target lowered to $12 from $17 at Wells Fargo

Alec Stranahan

Bank of America Securities

$14

Hold

64.32%

Upside

Reiterated

11/07/25

Intellia Therapeutics: Hold Rating Amid Safety Concerns and Regulatory Challenges

Gena Wang

Barclays

$24→$14

Buy

64.32%

Upside

Reiterated

11/07/25

Intellia Therapeutics (NTLA) Gets a Buy from Barclays

Brian Cheng

J.P. Morgan

Sell

-41.31%

Downside

Downgraded

11/07/25

J.P. Morgan downgrades Intellia Therapeutics (NTLA) to a Sell

Jack Allen

Robert W. Baird

$9→$4

Hold

-53.05%

Downside

Reiterated

11/07/25

Intellia Therapeutics price target lowered to $4 from $9 at BairdIntellia Therapeutics price target lowered to $4 from $9 at Baird

Geulah Livshits

Chardan Capital

$48→$26

Buy

205.16%

Upside

Reiterated

11/06/25

Analysts Conflicted on These Healthcare Names: Intellia Therapeutics (NASDAQ: NTLA), Relay Therapeutics (NASDAQ: RLAY) and Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Myles Minter

William Blair

―

Hold

―

Reiterated

11/15/25

Debanjana Chatterjee

JonesTrading

―

Hold

―

Downgraded

11/11/25

JonesTrading downgrades Intellia Therapeutics (NTLA) to a Hold

Andy Chen

Wolfe Research

―

Hold

―

Downgraded

11/11/25

Intellia Therapeutics downgraded to Peer Perform from Outperform at Wolfe ResearchIntellia Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research

Jonathan Miller

Evercore ISI

$17→$8

Hold

-6.10%

Downside

Downgraded

11/11/25

Intellia Therapeutics (NTLA) was downgraded to a Hold Rating at Evercore ISI

Unknown Analyst

Wedbush

Not Ranked

Wedbush

$9→$7

Hold

-17.84%

Downside

Reiterated

11/11/25

Wedbush Keeps Their Hold Rating on Intellia Therapeutics (NTLA)

Joon Lee

Truist Financial

$25→$14

Buy

64.32%

Upside

Reiterated

11/10/25

Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NASDAQ: NTLA), Tandem Diabetes Care (NASDAQ: TNDM) and Palvella Therapeutics (NASDAQ: PVLA)

Mitchell Kapoor

H.C. Wainwright

$18→$15

Buy

76.06%

Upside

Reiterated

11/10/25

Intellia Therapeutics price target lowered to $15 from $18 at H.C. WainwrightIntellia Therapeutics price target lowered to $15 from $18 at H.C. Wainwright

Jay Olson

Oppenheimer

$33→$27

Buy

216.90%

Upside

Reiterated

11/07/25

Intellia Therapeutics price target lowered to $27 from $33 at OppenheimerIntellia Therapeutics price target lowered to $27 from $33 at Oppenheimer

Silvan Tuerkcan

Citizens JMP

$29→$21

Buy

146.48%

Upside

Reiterated

11/07/25

Intellia Therapeutics price target lowered to $21 from $29 at Citizens JMPIntellia Therapeutics price target lowered to $21 from $29 at Citizens JMP

Yanan Zhu

Wells Fargo

$17→$12

Hold

40.85%

Upside

Reiterated

11/07/25

Intellia Therapeutics price target lowered to $12 from $17 at Wells FargoIntellia Therapeutics price target lowered to $12 from $17 at Wells Fargo

Alec Stranahan

Bank of America Securities

$14

Hold

64.32%

Upside

Reiterated

11/07/25

Intellia Therapeutics: Hold Rating Amid Safety Concerns and Regulatory Challenges

Gena Wang

Barclays

$24→$14

Buy

64.32%

Upside

Reiterated

11/07/25

Intellia Therapeutics (NTLA) Gets a Buy from Barclays

Brian Cheng

J.P. Morgan

Sell

-41.31%

Downside

Downgraded

11/07/25

J.P. Morgan downgrades Intellia Therapeutics (NTLA) to a Sell

Jack Allen

Robert W. Baird

$9→$4

Hold

-53.05%

Downside

Reiterated

11/07/25

Intellia Therapeutics price target lowered to $4 from $9 at BairdIntellia Therapeutics price target lowered to $4 from $9 at Baird

Geulah Livshits

Chardan Capital

$48→$26

Buy

205.16%

Upside

Reiterated

11/06/25

Analysts Conflicted on These Healthcare Names: Intellia Therapeutics (NASDAQ: NTLA), Relay Therapeutics (NASDAQ: RLAY) and Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Intellia Therapeutics

1 Month

xxx

Success Rate

15/37 ratings generated profit

Average Return

-0.05%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 40.54% of your transactions generating a profit, with an average return of -0.05% per trade.

3 Months

xxx

Success Rate

13/36 ratings generated profit

Average Return

+11.08%

reiterated a xxx

rating 24 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 36.11% of your transactions generating a profit, with an average return of +11.08% per trade.

1 Year

Geulah LivshitsChardan Capital

Success Rate

12/36 ratings generated profit

Average Return

+87.09%

reiterated a buy rating 24 days ago

Copying Geulah Livshits's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +87.09% per trade.

2 Years

xxx

Success Rate

9/36 ratings generated profit

Average Return

+25.44%

reiterated a xxx

rating 24 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 25.00% of your transactions generating a profit, with an average return of +25.44% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NTLA Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NTLA has received 27 Buy Ratings, 25 Hold Ratings, and 2 Sell Ratings. NTLA average Analyst price target in the past 3 months is 15.97.

Each month's total comprises the sum of three months' worth of ratings.

NTLA Financial Forecast

NTLA Earnings Forecast

Next quarter’s earnings estimate for NTLA is -$0.96 with a range of -$1.10 to -$0.81. The previous quarter’s EPS was -$0.92. NTLA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year NTLA has Performed in-line its overall industry.

NTLA Sales Forecast

Next quarter’s sales forecast for NTLA is $12.05M with a range of $0.00 to $16.25M. The previous quarter’s sales results were $13.78M. NTLA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year NTLA has Performed in-line its overall industry.

NTLA Stock Forecast FAQ

What is NTLA’s average 12-month price target, according to analysts?

Based on analyst ratings, Intellia Therapeutics’s 12-month average price target is 15.97.

What is NTLA’s upside potential, based on the analysts’ average price target?

Intellia Therapeutics has 87.44% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NTLA a Buy, Sell or Hold?

Intellia Therapeutics has a consensus rating of Moderate Buy which is based on 9 buy ratings, 12 hold ratings and 1 sell ratings.

What is Intellia Therapeutics’s price target?

The average price target for Intellia Therapeutics is 15.97. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $54.00 ,the lowest forecast is $4.00. The average price target represents 87.44% Increase from the current price of $8.52.

What do analysts say about Intellia Therapeutics?

Intellia Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 22 Wall Streets Analysts.

How can I buy shares of NTLA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Intellia Therapeutics (NTLA) Stock Forecast & Price Target

NTLA Analyst Ratings

NTLA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Intellia Therapeutics

NTLA Analyst Recommendation Trends

NTLA Financial Forecast

NTLA Earnings Forecast

NTLA Sales Forecast

NTLA Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts